JPWO2022132195A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022132195A5 JPWO2022132195A5 JP2023536049A JP2023536049A JPWO2022132195A5 JP WO2022132195 A5 JPWO2022132195 A5 JP WO2022132195A5 JP 2023536049 A JP2023536049 A JP 2023536049A JP 2023536049 A JP2023536049 A JP 2023536049A JP WO2022132195 A5 JPWO2022132195 A5 JP WO2022132195A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- repressor
- seq
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims description 153
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 230000008685 targeting Effects 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 239000012636 effector Substances 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 23
- 230000001629 suppression Effects 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 230000035899 viability Effects 0.000 claims description 12
- 229940125763 bromodomain inhibitor Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- 238000003570 cell viability assay Methods 0.000 claims description 6
- 229940043355 kinase inhibitor Drugs 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 229940124647 MEK inhibitor Drugs 0.000 claims description 4
- -1 e.g. Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004066 trametinib Drugs 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102000016397 Methyltransferase Human genes 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 2
- 230000002137 anti-vascular effect Effects 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000032823 cell division Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 238000011521 systemic chemotherapy Methods 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 239000000047 product Substances 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 2
- 230000003833 cell viability Effects 0.000 claims 2
- 230000001973 epigenetic effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 3
- 208000007300 Fibrolamellar hepatocellular carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 201000004098 fibrolamellar carcinoma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125833P | 2020-12-15 | 2020-12-15 | |
| US63/125,833 | 2020-12-15 | ||
| US202163137097P | 2021-01-13 | 2021-01-13 | |
| US63/137,097 | 2021-01-13 | ||
| US202163212991P | 2021-06-21 | 2021-06-21 | |
| US63/212,991 | 2021-06-21 | ||
| US202163281022P | 2021-11-18 | 2021-11-18 | |
| US63/281,022 | 2021-11-18 | ||
| PCT/US2021/010059 WO2022132195A2 (en) | 2020-12-15 | 2021-12-15 | Compositions and methods for modulation myc expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553490A JP2023553490A (ja) | 2023-12-21 |
| JP2023553490A5 JP2023553490A5 (https=) | 2024-12-23 |
| JPWO2022132195A5 true JPWO2022132195A5 (https=) | 2024-12-23 |
Family
ID=82060102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536049A Pending JP2023553490A (ja) | 2020-12-15 | 2021-12-15 | Ｍｙｃ発現を調節するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240132559A1 (https=) |
| EP (1) | EP4262849A4 (https=) |
| JP (1) | JP2023553490A (https=) |
| KR (1) | KR20230120138A (https=) |
| AU (1) | AU2021401231A1 (https=) |
| CA (1) | CA3205133A1 (https=) |
| MX (1) | MX2023007116A (https=) |
| WO (1) | WO2022132195A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7682604B2 (ja) | 2016-09-07 | 2025-05-26 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | 遺伝子発現をモジュレートするための方法および組成物 |
| CN115192714B (zh) * | 2022-07-08 | 2024-09-17 | 沈阳药科大学 | Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024238723A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| WO2024238726A1 (en) | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating methylation of a target gene |
| WO2024243438A2 (en) * | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025019742A1 (en) | 2023-07-19 | 2025-01-23 | Omega Therapeutics, Inc. | Methods and compositions for modulating ctnnb1 expression |
| WO2025064469A1 (en) * | 2023-09-18 | 2025-03-27 | Omega Therapeutics, Inc. | Methods for assessing dosage for epigenetic modifying agents |
| WO2025144907A1 (en) * | 2023-12-27 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Kinase inhibitors and particles comprising myc modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997011972A1 (en) * | 1995-09-28 | 1997-04-03 | The Trustees Of Columbia University In The City Of New York | Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof |
| GB201119904D0 (en) * | 2011-11-17 | 2011-12-28 | Univ Vilnius | Analysis of methylation sites |
| US20170369855A1 (en) * | 2014-12-24 | 2017-12-28 | Dana-Farber Cancer Institute, Inc. | Systems and methods for genome modification and regulation |
| KR101900278B1 (ko) * | 2016-04-18 | 2018-09-19 | 건국대학교 글로컬산학협력단 | Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법 |
| WO2018111944A1 (en) * | 2016-12-12 | 2018-06-21 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| JP2020515258A (ja) * | 2017-03-31 | 2020-05-28 | アジェノビア コーポレーション | 抗ウイルス治療剤 |
| US20190233805A1 (en) * | 2017-10-04 | 2019-08-01 | The Regents Of The University Of California | Targetable proteins for epigenetic modification and methods for use thereof |
| US20220380760A1 (en) * | 2018-10-15 | 2022-12-01 | Flagship Pioneering Innovations V, Inc. | Disrupting genomic complex assembly in fusion genes |
| US11866469B2 (en) * | 2019-02-06 | 2024-01-09 | Klogenix Llc | DNA binding proteins and uses thereof |
-
2021
- 2021-12-15 KR KR1020237024060A patent/KR20230120138A/ko active Pending
- 2021-12-15 MX MX2023007116A patent/MX2023007116A/es unknown
- 2021-12-15 EP EP21907332.7A patent/EP4262849A4/en active Pending
- 2021-12-15 US US18/257,483 patent/US20240132559A1/en active Pending
- 2021-12-15 CA CA3205133A patent/CA3205133A1/en active Pending
- 2021-12-15 JP JP2023536049A patent/JP2023553490A/ja active Pending
- 2021-12-15 AU AU2021401231A patent/AU2021401231A1/en active Pending
- 2021-12-15 WO PCT/US2021/010059 patent/WO2022132195A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | iRGD‐modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation | |
| Jiang et al. | Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression | |
| CN108486247A (zh) | piRNA-54265在结直肠癌的诊治和预后评价方面的应用 | |
| Lan et al. | Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness | |
| AU2024259837B2 (en) | ADP-ribose binding peptide having anticancer activity and use thereof | |
| CN110833546A (zh) | 通佐溴胺在治疗胃癌中的用途 | |
| Mishra et al. | Z‐Nucleic Acid Sensing and Activation of ZBP1 in Cellular Physiology and Disease Pathogenesis | |
| Jin et al. | Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance | |
| CN111671904B (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| Yu et al. | Super‐enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5‐FU Resistance in Gastric Cancer | |
| JPWO2022132195A5 (https=) | ||
| Ding et al. | ACT001 Suppresses the Malignant Progression of Small‐Cell Lung Cancer by Inhibiting Lactate Production and Promoting Anti‐Tumor Immunity | |
| US20240318147A1 (en) | Recombinant oncolytic virus, and construction method therefor and use thereof | |
| Lou et al. | Effect of GADD45G on the radioresistance of nasopharyngeal carcinoma cells | |
| CN117801064B (zh) | 一种多肽、药物和用途 | |
| Wan et al. | Engineered lung cell targeting and SLC7A11 siRNA expressing bacterial extracellular vesicles impair the progression of none‐small cell lung cancer | |
| WO2020155534A1 (zh) | 寡核苷酸分子及其在肿瘤治疗中的应用 | |
| US8729226B2 (en) | Cancer therapy method | |
| WO2005082422A1 (en) | Combination of ad-p53 and chemotherapy for the treatment of tumours | |
| KR20180129585A (ko) | Mage-1에 특이적으로 결합하는 압타머 및 이의 용도 | |
| Yang et al. | SOHLH2-RAD54L axis induces radioresistance by promoting homologous recombination repair in non-small cell lung cancer | |
| Dhahri et al. | Single amino-acid differences define H2B variants and modify chromatin accessibility to induce EMT in breast cancer | |
| CN121337994A (zh) | 抑制剂在制备治疗肺腺癌药物中的应用及治疗肺腺癌药物 | |
| Chen | Identification and Functional Characterization of ZincFinger Protein 488 as a Novel Therapeutic Target in KRASDriven Pancreatic Ductal Adenocarcinoma | |
| Xue et al. | EP300 Modulates MCM8 Transcription and Augments the Malignant Phenotype of Hepatitis B Virus–Positive Hepatocellular Carcinoma Cells |